have identified that TK1 expression is remarkably elevated in SLE bone marrow-derived MSCs (BM-MSCs), and silencing TK1 could alleviate inflammation, growth arrest, and senescence in BM-MSCs of SLE, highlighting TK1’s considerable promise as a therapeutic target against SLE (131). This evidence concerns the gene TK1 and systemic lupus erythematosus.